Inhibition of in vitro immunoglobulin production by a novel immunosuppressive drug brequinar sodium.
Moudgil
A
A
Toyoda
M
M
Wang
S J
SJ
Jaffee
B D
BD
Cramer
D V
DV
Makowka
L
L
Jordan
S
S
D000328:Adult; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D016572:Cyclosporine / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007070:Immunoglobulin A / Q000096:biosynthesis / Q000187:drug effects*; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000187:drug effects*; D007075:Immunoglobulin M / Q000096:biosynthesis / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology; D011043:Pokeweed Mitogens / Q000494:pharmacology; D016559:Tacrolimus / Q000008:administration & dosage / Q000494:pharmacology; D011798:Quinaldines
D001713:Biphenyl Compounds; D016572:Cyclosporine; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007166:Immunosuppressive Agents; D011043:Pokeweed Mitogens; D016559:Tacrolimus; C046943:brequinar; D011798:Quinaldines